BioSpace News Archive

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at 4:00pm ET.

About Avivagen Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.

Merck, known as MSD outside the United States and Canada, announced the presentation of findings from a systematic literature review and meta-analysis of data from real-world observational studies of PREVYMIS™ for primary prophylaxis of cytomegalovirus infection and disease in patients undergoing allogeneic hematopoietic cell transplantation who were CMV-seropositive.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced financial results for the fourth quarter ended December 31, 2021 and provided a corporate update.

Pfizer Inc. announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™, to 95 low- and middle-income countries, pending authorization or approval.

Orphazyme A/S announces that, following the receipt of the negative Trend Vote by the Committee for Medicinal Products for Human Use (CHMP) as announced on February 23, 2022 (please see company announcement no. 07/2022), the Company has decided to withdraw its European Marketing Authorisation Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease Type C.

NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2021 after market close on Tuesday, March 29, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

First Wave BioPharma, Inc. announced that James Sapirstein, Chairman and Chief Executive Officer, will deliver a virtual presentation at Maxim’s 2022 Virtual Growth Conference being held March 28 – 30, 2022.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced the appointment of industry veteran, Scott Dove, Ph.D., as Chief Operating Officer.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that the first patient has been dosed in the potentially registrational Phase 1/2 trial of ZN-d5, the Company’s oral selective BCL-2 inhibitor candidate for hematologic malignances and related disorders, in patients with relapsed or refractory light chain (AL) amyloidosis.